Loading...
XNAS
SMMT
Market cap12bUSD
Jul 09, Last price  
15.48USD
1D
-1.34%
1Q
-21.30%
Jan 2017
80.84%
IPO
50.44%
Name

Summit Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:SMMT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
60.81%
Rev. gr., 5y
165.43%
Revenues
0k
2,028,0006,025,000266,639301,945738,8021,116,2741,895,0001,844,0001,888,0001,281,0002,376,00014,168,00057,088,000611,872628,8751,337,701583,190000
Net income
-1.08b
L+510.72%
-5,924,000-20,128,000-32,289,000-5,342,118-7,422,000-4,230,394-4,225,000-6,093,000-11,384,000-20,137,000-21,371,000-20,158,00010,869,000-23,986,558-38,534,681-65,518,520-65,170,046-482,367,000-176,773,000-1,079,586,000
CFO
-240m
L+111.06%
-5,959,082-16,126,787-14,721,397-2,645,620-4,336,060-3,801,702-5,033,880-9,680,984-16,587,313-24,470,55415,175,680-20,580,908-35,106,000-26,663,000-35,337,890-53,807,000-33,897,438-60,744,354-113,555,483-239,665,728

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
URL
https://www.smmttx.com/
IPO date
Oct 14, 2004
Employees
76
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122019‑012018‑012017‑01
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT